Drug Patents owned by Idorsia
1. List of Quviviq drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9732075 | IDORSIA | Benzimidazole-proline derivatives |
Jun, 2033
(10 years from now) | |
| US9790208 | IDORSIA | Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
Dec, 2034
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10023560 | IDORSIA | Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
Dec, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 7, 2027 |
Drugs and Companies using DARIDOREXANT HYDROCHLORIDE ingredient
NCE-1 date: 2026-04-07
Market Authorisation Date: 07 April, 2022
Treatment: Treatment of insomnia
Dosage: TABLET;ORAL
More Information on Dosage
QUVIVIQ family patents
7
United States
4
Korea, Republic of
4
European Union
3
Singapore
3
IB
3
Taiwan, Province of China
3
EA
3
Lithuania
3
Hungary
2
Portugal
2
Malaysia
2
Spain
2
Croatia
2
New Zealand
2
Norway
2
Philippines
2
Mexico
2
Morocco
2
China
2
Hong Kong
2
South Africa
2
Canada
2
Japan
2
Cyprus
2
Slovenia
2
Ukraine
2
Israel
2
Poland
2
Chile
2
Australia
2
Denmark
1
Brazil
1
Argentina
1
Saudi Arabia
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic